浆细胞疾病患者接种COVID-19疫苗后抗体与T细胞应答的超深度T细胞受体免疫测序研究
本研究在浆细胞疾病(PCD)患者中评估COVID-19疫苗接种后的抗体和病毒特异性T细胞应答,采用超深度T细胞受体(TCR)免疫测序。364例PCD患者完成spike抗体检测,其中56例接受TCR免疫测序。接种后6个月内检测者中86%可检出spike抗体,接种后TCR中与COVID-19基因组表面糖蛋白区域相关的比例升高,提示spike特异性T细胞应答。
要点
- 接种后6个月内检测的PCD患者中86%可检出spike抗体。
- 年龄增长、使用抗CD38或抗B细胞成熟抗原治疗、接种BNT162b2(较mRNA-1273)与较低抗体滴度相关。
- 无抗体应答的患者也可出现spike特异性T细胞应答。
核心结论
- 尽管PCD患者常因基础疾病和治疗而处于免疫抑制状态,COVID-19疫苗接种仍可引发体液和T细胞应答,仍是该人群的重要干预措施。
研究设计与样本
- 研究纳入364例浆细胞疾病(PCD)患者,在完成初始两剂mRNA疫苗或一剂JNJ-78436735后≥2周进行spike受体结合域IgG抗体检测。
- 其中56例患者在接种疫苗后接受T细胞受体(TCR)免疫测序。
主要发现
- 接种后6个月内检测的患者中,86%可检出spike抗体。
- 年龄增长、使用抗CD38或抗B细胞成熟抗原治疗、接种BNT162b2(较mRNA-1273)与较低抗体滴度相关。
- 接种后TCR中与COVID-19基因组表面糖蛋白区域相关的比例升高,与spike特异性T细胞应答一致。
- spike特异性T细胞中位广度(breadth)为3.11×10-5,与健康人群接种后相当;spike特异性T细胞广度与抗体滴度相关,但无抗体应答的患者也出现spike特异性T细胞应答。
- 接受mRNA-1273者的spike特异性T细胞中位广度高于接受BNT162b2者(p=0.01)。
临床怎么用
- 作者认为,COVID-19疫苗接种仍可作为浆细胞疾病患者的重要干预措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated antibody and coronavirus disease 2019 (COVID-19)-specific T-cell mediated responses via ultra-deep immunosequencing of the T-cell receptor (TCR) repertoire in patients with plasma cell dyscrasias (PCD). We identified 364 patients with PCD who underwent spike antibody testing using commercially available spike-receptor binding domain immunoglobulin G antibodies ≥2 weeks after completion of the initial two doses of mRNA vaccines or one dose of JNJ-78436735. A total of 56 patients underwent TCR immunosequencing after vaccination. Overall, 86% tested within 6 months of vaccination had detectable spike antibodies. Increasing age, use of anti-CD38 or anti-B-cell maturation antigen therapy, and receipt of BNT162b2 (vs. mRNA-1273) were associated with lower antibody titres. We observed an increased proportion of TCRs associated with surface glycoprotein regions of the COVID-19 genome after vaccination, consistent with spike-specific T-cell responses. The median spike-specific T-cell breadth was 3.11 × 10-5 , comparable to those in healthy populations after vaccination. Although spike-specific T-cell breadth correlated with antibody titres, patients without antibody responses also demonstrated spike-specific T-cell responses. Patients receiving mRNA-1273 had higher median spike-specific T-cell breadth than those receiving BNT162b2 (p = 0.01). Although patients with PCD are often immunocompromised due to underlying disease and treatments, COVID-19 vaccination can still elicit humoral and T-cell responses and remain an important intervention in this patient population.
引用
- Chung A, Banbury B, Vignali M, et al. Antibody and T-cell responses by ultra-deep T-cell receptor immunosequencing after COVID-19 vaccination in patients with plasma cell dyscrasias. Br J Haematol. 2022. PMID: 36041779. doi:10.1111/bjh.18434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。